Goldenwell Biotech, Inc.: Business Overview, Financials & Competitive Analysis
Goldenwell Biotech, Inc. scores 2/10 on the AskCyborg Cyborg Score (Challenged). Early-stage biotech supplement company with significant cash constraints, minimal revenue, and substantial going concern risks. The company exhibits fundamental operational and financial challenges including minimal revenue generation, accumulated losses exceeding $1.3 million, acute cash constraints, and going concern doubts. Filing delays further suggest governance or operational strain.
What is Goldenwell Biotech, Inc.'s industry? Goldenwell Biotech, Inc. operates in Functional Foods and Beverages. AskCyborg classifies Goldenwell Biotech, Inc. under Functional Foods and Beverages in its company registry.
Goldenwell Biotech focuses on nutraceutical and dietary supplements business in the United States. The company is developing JI MAI (a bovine cardiac vascular active peptide), Double Proline AG (a 3D active collagen p...
Cyborg Score thesis
Early-stage biotech supplement company with significant cash constraints, minimal revenue, and substantial going concern...
Read the full analyst-debate transcript →Get the Latest Goldenwell Biotech, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeGoldenwell Biotech, Inc. Overview
Pro stress-test →Goldenwell Biotech focuses on nutraceutical and dietary supplements business in the United States. The company is developing JI MAI (a bovine cardiac vascular active peptide), Double Proline AG (a 3D active collagen peptide drinkable cosmetic), Cartilage Peptide (a Type II collagen peptide), and Sugar Master (a dietary supplement).
Strategic Profile
Pro stress-test →As of September 30, 2025, the company had trailing 12-month revenue of $62.5K. Management has identified substantial doubt about the company's ability to continue as a going concern due to its accumulated net loss of $1,331,643 since inception. In March 2026, Goldenwell Biotech filed an NT 10-K notification indicating it could not timely compile its Form 10-K for the year ended December 31, 2025, and expects to file by April 15, 2026.
Competitive Landscape
Pro stress-test →Goldenwell Biotech competes in the crowded nutraceutical and dietary supplement market against established brands. Direct competitors include large-cap supplement manufacturers and private label producers. The company's peptide-based formulations (collagen, bovine peptides) position it in the performance supplement segment, competing with brands like USANA, Herbalife, and smaller specialized peptide supplement makers. Limited market presence and severe capital constraints significantly disadvantage the company versus established competitors.
Industry Context
Goldenwell Biotech, Inc. operates in Functional Foods and Beverages.
Key facts
Founded: 2019 · Headquarters: Hudson, Ohio · Revenue: $62.5K · Market cap: $104M